Emergencies in Huntington’s Disease

  • Kathleen M. ShannonEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Huntington’s disease is a rare, dominantly inherited degenerative disease of the central nervous system characterized by gradually progressive motor and cognitive impairment and a panoply of psychiatric manifestations. Emergencies in HD generally relate to complications of immobility (respiratory disorders and injuries due to falls), or to acute psychiatric morbidity or complications of psychiatric treatment. Clinicians must remain vigilant to acute changes in HD, since clinical changes may be wrongly attributed to the underlying disease, and patients themselves may have reduced awareness of their symptoms or their complications. Emergencies in HD may cause premature death or contribute to poor quality of life in this population.


Suicidal Ideation Neuroleptic Malignant Syndrome Berg Balance Scale Soft Neurological Sign Aspiration Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Harper PS. The epidemiology of Huntington’s disease. Hum Genet. 1992;89:365–76.PubMedCrossRefGoogle Scholar
  2. 2.
    James CM, Houlihan GD, Snell RG, Cheadle JP, Harper PS. Late-onset Huntington’s disease: a clinical and molecular study. Age Ageing. 1994;23:445–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Nance MA, Mathias-Hagen V, Breningstall G, Wick MJ, McGlennen RC. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington’s disease. Neurology. 1999;52:392–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Nance MA, Myers RH. Juvenile onset Huntington’s disease–clinical and research perspectives. Ment Retard Dev Disabil Res Rev. 2001;7:153–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62:1341–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Biglan KM, Ross CA, Langbehn DR, et al. Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov Disord. 2009;24:1763–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Penney Jr JB, Young AB, Shoulson I, et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5:93–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington’s disease: dementia criteria revisited. Mov Disord. 2010;25:1163–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington’s disease. Neurology. 2003;61:1702–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Paulsen JS, Conybeare RA. Cognitive changes in Huntington’s disease. Adv Neurol. 2005;96:209–25.PubMedGoogle Scholar
  12. 12.
    Anderson KE, Marshall FJ. Behavioral symptoms associated with Huntington’s disease. Adv Neurol. 2005;96:197–208.PubMedGoogle Scholar
  13. 13.
    Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2001;71:310–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington’s disease. Arch Neurol. 1996;53:493–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wheelock VL, Tempkin T, Marder K, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60:998–1001.PubMedCrossRefGoogle Scholar
  16. 16.
    Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov Disord. 1996;11:542–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Walker FO. Huntington’s disease. Lancet. 2007;369:218–28.PubMedCrossRefGoogle Scholar
  18. 18.
    Dubinsky RM. No going home for hospitalized Huntington’s disease patients. Mov Disord. 2005;20:1316–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington’s disease at death. A case–control study. Arch Neurol. 1988;45:878–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Sorensen SA, Fenger K. Causes of death in patients with Huntington’s disease and in unaffected first-degree relatives. J Med Genet. 1992;29:911–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Kagel MC, Leopold NA. Dysphagia in Huntington’s disease: a 16-year retrospective. Dysphagia. 1992;7:106–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Heemskerk AW, Roos RA. Dysphagia in Huntington’s disease: a review. Dysphagia. 2010;26:62–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Moskowitz CB, Marder K. Palliative care for people with late-stage Huntington’s disease. Neurol Clin. 2001;19:849–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington’s disease. Mov Disord. 2008;23:1100–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Grimbergen YA, Knol MJ, Bloem BR, Kremer BP, Roos RA, Munneke M. Falls and gait disturbances in Huntington’s disease. Mov Disord. 2008;23:970–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Gennarelli TA, Thibault LE. Biomechanics of acute subdural hematoma. J Trauma. 1982;22:680–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Maxeiner H, Wolff M. Pure subdural hematomas: a postmortem analysis of their form and bleeding points. Neurosurgery. 2002;50:503–8. discussion 508–509.PubMedGoogle Scholar
  28. 28.
    Pechlivanis I, Andrich J, Scholz M, Harders A, Saft C, Schmieder K. Chronic subdural haematoma in patients with Huntington’s disease. Br J Neurosurg. 2006;20:327–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A. Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007;29:365–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Busse ME, Wiles CM, Rosser AE. Mobility and falls in people with Huntington’s disease. J Neurol Neurosurg Psychiatry. 2009;80:88–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Kloos AD, Kegelmeyer DA, Young GS, Kostyk SK. Fall risk assessment using the Tinetti mobility test in individuals with Huntington’s disease. Mov Disord. 2010;25:2838–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Clinical measurement of mobility and balance impairments in Huntington’s disease: validity and responsiveness. Gait Posture. 2009;29:433–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Miles SH. Restraints and sudden death. J Am Geriatr Soc. 1993;41:1013.PubMedGoogle Scholar
  34. 34.
    Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol. 2001;58:273–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17:496–502.PubMedCrossRefGoogle Scholar
  36. 36.
    Huntington G. On Chorea. Med Surg Reporter. 1872;26:317–21.Google Scholar
  37. 37.
    Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Suicide risk in Huntington’s disease. J Med Genet. 1993;30:293–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry. 2005;162:725–31.PubMedCrossRefGoogle Scholar
  39. 39.
    Fiedorowicz JG, Mills JA, Ruggle A, Langbehn D, Paulsen JS. Suicidal Behavior in Prodromal Huntington Disease. Neurodegener Dis. 2011;8(6):483–90. Epub 2011 Jun 9.PubMedCrossRefGoogle Scholar
  40. 40.
    Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24:305–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS, Clark E. Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47:1283–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Tetrabenazine as antichorea therapy in Huntington disease. a randomized controlled trial. Neurology. 2006;66:366–72.CrossRefGoogle Scholar
  43. 43.
    Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-­based review. Curr Pharm Des. 2006;12:2701–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137–45.PubMedGoogle Scholar
  45. 45.
    Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies part 1–hypokinetic disorders. Arch Neurol. 2011;68:567–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology. 1981;31:1022–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant ­syndrome. Mov Disord. 1996;11:95.PubMedCrossRefGoogle Scholar
  48. 48.
    Gahr M, Orth M, Abler B. Neuroleptic malignant syndrome with aripiprazole in Huntington’s disease. Mov Disord. 2010;25:2475–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurological SciencesRush Medical College, Rush University Medical CenterChicagoUSA

Personalised recommendations